These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
Auspex is expected to seek U.S. approval for SD-809 next year.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.
New Adcetris data are from a phase III study known AETHERA are being presented in full at the American Society of Hematology (ASH) annual meeting underway in San Francisco.
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics
while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a
reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV